Free Trial
NASDAQ:JSPR

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Jasper Therapeutics logo
$2.40 -0.09 (-3.61%)
Closing price 04:00 PM Eastern
Extended Trading
$2.40 +0.00 (+0.04%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Advanced

Key Stats

Today's Range
$2.39
$2.53
50-Day Range
$2.33
$3.11
52-Week Range
$2.21
$26.05
Volume
234,804 shs
Average Volume
431,702 shs
Market Capitalization
$39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.63
Consensus Rating
Hold

Company Overview

Jasper Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

JSPR MarketRank™: 

Jasper Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 284th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Jasper Therapeutics has a consensus price target of $25.63, representing about 967.7% upside from its current price of $2.40.

  • Amount of Analyst Coverage

    Jasper Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Jasper Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($4.47) to ($4.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jasper Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jasper Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Jasper Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Jasper Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.86% of the float of Jasper Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Jasper Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Jasper Therapeutics has recently increased by 3.57%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Jasper Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Jasper Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.86% of the float of Jasper Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Jasper Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Jasper Therapeutics has recently increased by 3.57%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Jasper Therapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Jasper Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    21 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 320% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jasper Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $347,490.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Jasper Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Jasper Therapeutics' insider trading history.
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JSPR Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
See More Headlines

JSPR Stock Analysis - Frequently Asked Questions

Jasper Therapeutics' stock was trading at $21.38 at the start of the year. Since then, JSPR shares have decreased by 88.8% and is now trading at $2.40.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) issued its earnings results on Wednesday, August, 13th. The company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.54.

Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
8/13/2025
Today
10/06/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JSPR
CIK
1788028
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$65.00
Low Price Target
$5.00
Potential Upside/Downside
+967.7%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$71.27 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-172.28%
Return on Assets
-128.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.10
Quick Ratio
2.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.11 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
16,253,000
Free Float
15,505,000
Market Cap
$39.01 million
Optionable
Optionable
Beta
2.79

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:JSPR) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners